Strides Arcolab reportedly signed a deal with Gilead Sciences Inc to sell low-cost generic versions of latter's HIV medicine 'emtricitabine' in developing countries.
According to reports, the Indian firm would also promote fixed-dose combinations of emtricitabine, co-formulated with other Gilead HIV medicines.
Strides Arcolab said it has "entered into an in-licensing agreement to collaborate with Gilead Sciences Inc to promote access to high-quality, low-cost generic versions of Gilead's HIV medicine emtricitabine (FTC) in developing countries".
In the agreement, Gilead will provide technology transfer for the manufacture of emtricitabine, together with investment assistance for process improvements to reduce overall manufacturing costs, reports added.